

[Meet the Professor]

21st Meet The Professor Advanced International Breast Cancer Course (AIBCC)

Padova, September 11-12, 2025

[Program]

Thursday, September 11

10.30 Introduction to the Conference
Pierfranco Conte, Valentina Guarneri, Philip Poortmans, Aleix Prat

SESSION I – EVOLVING KNOWLEDGE OF BREAST CANCER BIOLOGY: IMPLICATIONS FOR STAGING, PROGNOSIS AND PREDICTION

Chairpersons: Pierfranco Conte, Aleix Prat

11.00 Gene expression tools in early-stage HR+/HER2- breast cancer: questioning the grey areas
Alberto Zambelli

11.20 The immune system and breast cancer: TNBC and beyond
Maria Vittoria Dieci

11.40 DNA NGS-based biomarkers to inform treatment sequence in advanced breast cancer
Mafalda Oliveira

12.00 Tackling the biological diversity in HER2-positive breast cancer: clinical implications
Aleix Prat

12.20 Discussion

12.50 *Lunch*

SESSION II – GENETIC PREDISPOSITION TO BREAST CANCER

Chairpersons: Bettina Borisch, Fedro Peccatori

14.00 Genetic testing beyond BRCA
Teresa Ramon y Cajal

14.20 Challenges in locoregional treatments:
- the surgeon's view - Eleftherios Mamounas
- the radiation oncologist's view - Jacek Jassem
- the patient's view point - Bettina Borisch

15.00 Systemic treatment options in patients with genetic predisposition with Early and Advanced disease
Sandra Swan

15.30 Discussion

16.00 *Coffee break*

SESSION III – EARLY BREAST CANCER: NEOADJUVANT AND POST-NEOADJUVANT THERAPY

Chairpersons: Giuseppe Curigliano, Sibylle Loibl

16.20 Modulation of neoadjuvant and post-neoadjuvant treatment in HER2+
Sibylle Loibl

16.40 Modulation of neoadjuvant and post-neoadjuvant treatment in TNBC
Hope Rugo

- 17.00 Neoadjuvant Treatment in HR+HER2-BC: why, when, which one
Valentina Guarneri
- 17.20 Response-guided radiotherapy after neoadjuvant treatments
Angel Montero Luis
- 17.40 Discussion
- 18.00 Ceremony for the presentation of the University of Padua Award for Advances in Breast Cancer 2025
- 18.15 **Lecture of the Awardee**
- 18.45 Adjourn

Friday, September 12

SESSION IV – EARLY BREAST CANCER

Chairpersons: Lucia del Mastro, Michelino De Laurentiis

- 9.00 Enhancing efficacy of hormonal therapy in early breast cancer
Stephen Johnston
- 9.20 Adjuvant treatments for rare histologies: how to manage uncertainty
Fatima Cardoso
- 9.40 Life style intervention after breast cancer
Claudio Vernieri
- 10.00 Discussion
- 10.30 *Coffee break*
- 11.00 **Clinical Multidisciplinary Shooting Session 1 – Early Breast Cancer**
Panelists: Lucia Del Mastro, Michelino De Laurentiis, Hesham Ahmed Gaballah Elghazaly, Stephen Johnston, Eleftherios Mamounas, Philip Poortmans, Hope Rugo, Sandra Swain
- 12.30 *Lunch*

SESSION V – METASTATIC BREAST CANCER: STATE OF ART AND TRIALS LIKELY TO IMPACT IN THE FUTURE

Chairpersons: Alessandra Gennari, Fabio Puglisi

- 13.30 HR+ disease
Laura Biganzoli
- 14.00 HER2+ disease
Giuseppe Curigliano
- 14.30 Triple negative disease
Giampaolo Bianchini
- 15.00 Discussion

15.20 Clinical Multidisciplinary Shooting Session 2 – Advanced Breast Cancer

Panelists: Hesham Ahmed Gaballah Elghazaly , Alessandra Gennari, Jacek Jassem, Stephen Johnston, Eleftherios Mamounas, Fabio Puglisi, Sandra Swain, Hope Rugo

16.40 Take home messages and adjourn

Pierfranco Conte, Valentina Guarneri, Aleix Prat, Philip Poortmans

[Aims]

Breast cancer research has been the frontrunner in many fields of cancer research: epidemiology, life-style and genetic risk factors, secondary prevention, conservative surgery, molecular classification, curative adjuvant therapies, neoadjuvant treatments, targeted agents, survival prolongation in advanced stages. Thanks to this knowledge, today many breast cancers can be prevented, most can be diagnosed at early stages and cured and the minority of patients at advanced stages can still enjoy a significant survival with a reasonable quality of life.

As a consequence of these major improvements, the bar of research and clinical excellence for breast cancer has raised even more.

New prognostic and predictive biomarkers are available, need to be validated and to be implemented in trial design and clinical practice. Risk-adapted surgery and radiation therapy allow for less and less invasive procedures. Multiple effective adjuvant therapies in the different molecular breast cancer subtypes, require a more precise definition of risk and predictivity of drug efficacy, to allow for a rational de-escalation or escalation of curative treatments. The impressive advances in the treatment of advanced breast cancers, envisage the possibility of cure with a multimodality approach for some patients and guarantee a prolonged survival for most of them with a rational sequencing of treatments.

The 21st AIBCC in Padova, will allow to sum up the most recent biological and clinical achievements and to allow an open and friendly discussion of clinical cases among key opinion leaders and participants.

[Addressed to]

Gynaecologists and obstetrics, medical oncologists, pathologists, radiologists, radiation oncologists, surgeons. Biologists, pharmacists, and nurses.

[Directors]

Pierfranco Conte
Scientific Director
S. Camillo Hospital
IRCCS, Venezia (I)

Valentina Guarneri
Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padova (I)

Philip Poortmans
Former president of ESTRO and of ECCO
Department of Radiation Oncology
Iridium Network
University of Antwerp
Wilrijk-Antwerp (B)

Aleix Prat
Clinic Barcelona Comprehensive Cancer Center
University of Barcelona
Barcelona (ES)

[Scientific Committee]

Bettina Borisch
Institute of Global Health
University of Geneva

Maria Vittoria Dieci
Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padova (I)

Hesham Ahmed Gaballah Elghazaly
Department of Clinical Oncology and nuclear medicine
University of Ainshams
Cairo (EG)

Jacek Jassem
Department of Oncology and Radiotherapy
Medical University of Gdansk (PL)

Stephen Johnston
NIHR Biomedical Research Centre for Cancer
Royal Marsden NHS Foundation Trust & Institute of Cancer Research
London (UK)

Sibylle Loibl
German Breast Group
University of Frankfurt (D)

Eleftherios Mamounas
Comprehensive Breast Program
MD Anderson Cancer Center Orlando
Orlando (F)

Fedro Alessandro Peccatori
Department of Medical Oncology
European Institute of Oncology (IEO)
Milano (I)

Sandra Swain M.
Professor of Medicine, Associate Dean Research Development
Georgetown University Medical Center
Washington (USA)

[Speakers & Chairpersons]

Giampaolo Bianchini
Breast Unit
IRCCS Ospedale San Raffaele
Milano

Laura Biganzoli
Breast Unit
Nuovo Ospedale Santo Stefano
Azienda USL Toscana Centro
Prato (I)

Fatima Cardoso
ABC Global Alliance
Lisbon (P)

Giuseppe Curigliano
Department of Oncology
European Institute of Oncology
University of Milano (I)

Michelino De Laurentiis
Breast Unit
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Napoli (I)

Lucia Del Mastro
Division of Medical Oncology
IRCCS Ospedale Policlinico San Martino
Genova (I)

Alessandra Gennari
Division of Oncology
Ospedale Maggiore della Carità
UPO – University of Piemonte Orientale
Novara (I)

Angel Montero Luis
Radiation Oncology
Department of the Clara Campal Integral Oncology Center (CIOCC)
University Hospital
Madrid

Mafalda Oliveira
Medical Department of the Vall d'Hebron University
Hospital and Vall d'Hebron Institute of Oncology (VHIO)
Barcellona (E)

Fabio Puglisi
Departmente of Medical Oncology
Centro di Riferimento Oncologico (CRO) - IRCCS
University of Udine
Aviano – PN (I)

Hope Rugo
Breast Oncology Clinical Trials Program
UCSF Carol Franc Buck Breast Care Center
San Francisco (USA)

Teresa Ramon j Cajal
Transactional Genomics and Targeted Therapies in Solid Tumors
Clinic Barcelona
Barcelona (ES)

Claudio Vernieri
Division in Oncology
IRCCS Istituto Nazionale dei Tumori
Milano

Alberto Zambelli
Oncology Unit
ASST Papa Giovanni XXIII
Bergamo

[CME]

Based on the in force regulations approved by the CNFC, CME credits will be provided

[Meeting Venue]

Palazzo della Salute
Via San Francesco, 90
Padova